The Effect of Intravesical Instillation of Antifibrinolytic Agents on Bacillus Calmette-Guerin Treatment of Superficial Bladder Cancer: A Pilot Study

Journal of Urology

Volumn 179, Issue 4, 2008, Pages 1307-1312

  Pan, Chun Wu ^a   Shen, Zhou Jun ^a   Ding, Guo Qing ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

antifibrinolytic agents; BCG vaccine; complications; recurrence; urinary bladder neoplasms

Indexed keywords

4 AMINOMETHYLBENZOIC ACID; AMINOCAPROIC ACID; ANTIINFLAMMATORY AGENT; BCG VACCINE; MITOMYCIN C; PIRARUBICIN; SPASMOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUBERCULOSIS; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSURIA; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MICTURITION BURNING; MULTICENTER STUDY; ODYNURIA; PARTIAL THROMBOPLASTIN TIME; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TESTIS TUBERCULOSIS; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

4-AMINOBENZOIC ACID; 6-AMINOCAPROIC ACID; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; BCG VACCINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 40849094124     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.11.045     Document Type: Article

References (19)

1. Malkowicz S.B. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol 18 (2000) 280
2. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90
3. Brake M., Loertzer H., Horsch R., and Keller H. Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 55 (2000) 673
4. Lamm D.L., van der Meijden P.M., Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147 (1992) 596
5. Hudson M.A., Yuan J.J., Catalona W.J., and Ratliff T.L. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144 (1990) 1362
6. Hudson M.A., Brown E.J., Ritchey J.K., and Ratliff T.L. Modulation of fibronectin-mediated bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51 (1991) 3726
7. P'ng K.B., Walsh M.D., Seymour G.J., Lavin M.F., and Gardiner R.A. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer. Aust N Z J Surg 63 (1993) 127
8. Witjes J.A., vd Meijden A.P., Doesburg W., and Debruyne F.M. Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group. Eur Urol 23 (1993) 366
9. Shen Z., Ding G., and Chen Z. Enhancement of bacillus Calmette-Guerin attachment to the bladder wall: experimental study. Zhonghua Wai Ke Za Zhi 39 (2001) 951
10. Ratliff T.L., Palmer J.O., McGarr J.A., and Brown E.J. Intravesical bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guerin. Cancer Res 47 (1987) 1762
11. Kavoussi L.R., Brown E.J., Ritchey J.K., and Ratliff T.L. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85 (1990) 62
12. Hudson M.A., Ritchey J.K., Catalona W.J., Brown E.J., and Ratliff T.L. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 50 (1990) 3843
13. Laufer M., Kaver I., Sela B., and Matzkin H. Elevated urinary fibronectin levels after transurethral resection of bladder tumour: a possible role in patients failing therapy with bacillus Calmette-Guerin. BJU Int 84 (1999) 428
14. Zhang G.J., Chen F.H., Xu Y., Cao Y.L., Crist S., McKerrow A., et al. Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling. J Urol 172 (2004) 1496
15. Wierzbicka-Patynowski I., and Schwarzbauer J.E. The ins and outs of fibronectin matrix assembly. J Cell Sci 116 (2003) 3269
16. Sato J., Schorey J., Ploplis V.A., Haalboom E., Krahule L., and Castellino F.J. The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection. Am J Pathol 163 (2003) 517
17. Liu N., Makino T., Nogaki F., Kusano H., Suyama K., Muso E., et al. Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats. Am J Physiol Renal Physiol 287 (2004) 612
18. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671
19. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., Rodriguez R.H., Gomez J.M., Martin M.G., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242